GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SGX:T14) » Definitions » Cyclically Adjusted Price-to-FCF

Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Cyclically Adjusted Price-to-FCF : 85.00 (As of Jun. 05, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Tianjin Pharmaceutical Da Ren Tang Group Cyclically Adjusted Price-to-FCF?

As of today (2024-06-05), Tianjin Pharmaceutical Da Ren Tang Group's current share price is $2.55. Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $0.03. Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted Price-to-FCF for today is 85.00.

The historical rank and industry rank for Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

SGX:T14' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 52.81   Med: 92.07   Max: 650
Current: 77.73

During the past years, Tianjin Pharmaceutical Da Ren Tang Group's highest Cyclically Adjusted Price-to-FCF was 650.00. The lowest was 52.81. And the median was 92.07.

SGX:T14's Cyclically Adjusted Price-to-FCF is ranked worse than
77.33% of 322 companies
in the Drug Manufacturers industry
Industry Median: 32.255 vs SGX:T14: 77.73

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Tianjin Pharmaceutical Da Ren Tang Group's adjusted free cash flow per share data for the three months ended in Mar. 2024 was $-0.019. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.03 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Tianjin Pharmaceutical Da Ren Tang Group Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Pharmaceutical Da Ren Tang Group Cyclically Adjusted Price-to-FCF Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.09 66.42 93.26 69.32 72.26

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 94.36 110.14 87.62 72.26 61.66

Competitive Comparison of Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted Price-to-FCF falls into.



Tianjin Pharmaceutical Da Ren Tang Group Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=2.55/0.03
=85.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Tianjin Pharmaceutical Da Ren Tang Group's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.019/115.2271*115.2271
=-0.019

Current CPI (Mar. 2024) = 115.2271.

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.031 98.200 0.036
201409 0.013 98.900 0.015
201412 0.001 99.000 0.001
201503 0.027 99.900 0.031
201506 0.013 99.500 0.015
201509 -0.017 100.500 -0.019
201512 0.032 100.600 0.037
201603 0.019 102.200 0.021
201606 0.003 101.400 0.003
201609 0.000 102.400 0.000
201612 0.034 102.600 0.038
201703 -0.002 103.200 -0.002
201706 0.002 103.100 0.002
201709 -0.016 104.100 -0.018
201712 -0.007 104.500 -0.008
201803 0.031 105.300 0.034
201806 0.001 104.900 0.001
201809 0.008 106.600 0.009
201812 -0.003 106.500 -0.003
201903 0.016 107.700 0.017
201906 0.001 107.700 0.001
201909 0.010 109.800 0.010
201912 0.027 111.200 0.028
202003 0.015 112.300 0.015
202006 0.024 110.400 0.025
202009 0.013 111.700 0.013
202012 0.041 111.500 0.042
202103 0.015 112.662 0.015
202106 0.045 111.769 0.046
202109 0.054 112.215 0.055
202112 0.027 113.108 0.028
202203 0.007 114.335 0.007
202206 0.000 114.558 0.000
202209 0.004 115.339 0.004
202212 0.094 115.116 0.094
202303 0.027 115.116 0.027
202306 -0.016 114.558 -0.016
202309 -0.010 115.339 -0.010
202312 0.101 114.781 0.101
202403 -0.019 115.227 -0.019

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Tianjin Pharmaceutical Da Ren Tang Group  (SGX:T14) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Tianjin Pharmaceutical Da Ren Tang Group Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Tianjin Pharmaceutical Da Ren Tang Group's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Business Description

Traded in Other Exchanges
Address
No. 17 Baidi Road, Zhong Xin Mansion, Nankai District, Tianjin, CHN, 300193
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.

Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Headlines

No Headlines